Halozyme Appoints Michael LaBarre CSO
This article was originally published in Scrip
Executive Summary
Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, has promoted Dr. Michael J. LaBarre to chief scientific officer, succeeding Dr. Michael Shepard, who has been appointed a research fellow for the company. The move broadens LaBarre's responsibilities to include R&D of early pipeline assets, in addition to his role managing product development and Halozyme's Enhanze platform partnerships. Prior to joining Halozyme in 2008, he was vice-president, product development at Paramount BioSciences LLC; director, analytical and protein biochemistry, discovery research at Biogen Idec; and director analytical and formulation sciences, research and development at Idec Pharmaceuticals.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.